ArticleIBRO neuroscience reports2025
Exploring the effect and mechanism of
Article in IBRO neuroscience reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study explores the potential effects and mechanisms of SGD in treating pain in PD based on network pharmacology and molecular docking technology.The chemical components in the aqueous extract from SGD were identified using GC-MS analysis. A prediction network describing the relationship between SGD and pain in PD was established based on information collected from multiple databases. Using Gene Ontology (GO) enrichment and Kyoto Encyclopedia of Genes and Geomes (KEGG) pathway enrichment of key target genes in the DAVID6.8 database to obtain treatment target genes. To further investigate the molecular interactions, AutoDock Vina were employed to perform molecular docking and visualize the resulting outcomes. There were 206 targets obtained from the 105 active ingredients in Paeoniae Radix Alba and Radix Rhizoma Glycyrrhizae, and 5110 disease targets related to pain in PD were identified. GO enrichment analysis indicates that its Biologica Process (BP) involve response to lipopolysaccharide, response to metal ion. Cellular Component (CC) analysis suggests its primary impact on various membrane structural components. Molecular Function (MF) enrichment results primarily include ubiquitin-like protein ligase binding. KEGG pathway enrichment mainly encompasses MAPK, AGE-RAGE, IL-17, TNF, and Toll-like receptor signaling pathways. According to the results of molecular docking, the binding activity between core components and targets was marvelous (affinity < -5.0 kcal/mol). SGD has more advantages in the regulation of various types of pain in PD through multiple targets, which is worthy of further study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.